B Ozsvari
A myristoyl amide derivative of doxycycline potently targets cancer stem cells (CSCs) and prevents metastasis, without retaining antibiotic activity
Ozsvari, B; Magalhaes, LG; Latimer, J; Kangasmetsa, J; Sotgia, F; Lisanti, MP
Authors
LG Magalhaes
Dr Joe Latimer J.Latimer2@salford.ac.uk
Lecturer
J Kangasmetsa
Prof Federica Sotgia F.Sotgia@salford.ac.uk
Prof Michael Lisanti M.P.Lisanti@salford.ac.uk
Abstract
Here, we describe the chemical synthesis and biological activity of a new Doxycycline derivative, designed specifically to more effectively target cancer stem cells (CSCs). In this analogue, a myristic acid (14 carbon) moiety is covalently attached to the free amino group of 9-amino-Doxycycline. First, we determined the IC50 of Doxy-Myr using the 3D-mammosphere assay, to assess its ability to inhibit the anchorage-independent growth of breast CSCs, using MCF7 cells as a model system. Our results indicate that Doxy-Myr is >5-fold more potent than Doxycycline, as it appears to be better retained in cells, within a peri-nuclear membranous compartment. Moreover, Doxy-Myr did not affect the viability of the total MCF7 cancer cell population or normal fibroblasts grown as 2D-monolayers, showing remarkable selectivity for CSCs. Using both gram-negative and gram-positive bacterial strains, we also demonstrated that Doxy-Myr did not show antibiotic activity, against Escherichia coli and Staphylococcus aureus. Interestingly, other complementary Doxycycline amide derivatives, with longer (16 carbon; palmitic acid) or shorter (12 carbon; lauric acid) fatty acid chain lengths, were both less potent than Doxy-Myr for the targeting of CSCs. Finally, using MDA-MB-231 cells, we also demonstrate that Doxy-Myr has no appreciable effect on tumor growth, but potently inhibits tumor cell metastasis in vivo, with little or no toxicity. In summary, by using 9-amino-Doxycycline as a scaffold, here we have developed new chemical entities for their further development as anti-cancer agents. These compounds selectively target CSCs, e.g., Doxy-Myr, while effectively minimizing the risk of driving antibiotic resistance. Taken together, our current studies provide proof-of-principle, that existing FDA-approved drugs can be further modified and optimized, to successfully target the anchorage-independent growth of CSCs and the process of tumor cell metastasis. Based on these findings, we propose that it may be more appropriate to refer to tumor-spheres as metasta-spheres, to better reflect the close relationship between 3D anchorage-independent growth and metastasis.
Citation
Ozsvari, B., Magalhaes, L., Latimer, J., Kangasmetsa, J., Sotgia, F., & Lisanti, M. (2020). A myristoyl amide derivative of doxycycline potently targets cancer stem cells (CSCs) and prevents metastasis, without retaining antibiotic activity. Frontiers in Oncology, 10, 1528. https://doi.org/10.3389/fonc.2020.01528
Journal Article Type | Article |
---|---|
Acceptance Date | Jul 16, 2020 |
Online Publication Date | Sep 15, 2020 |
Publication Date | Sep 15, 2020 |
Deposit Date | Jul 29, 2020 |
Publicly Available Date | Sep 15, 2020 |
Journal | Frontiers in Oncology |
Publisher | Frontiers Media |
Volume | 10 |
Pages | 1528 |
DOI | https://doi.org/10.3389/fonc.2020.01528 |
Publisher URL | https://doi.org/10.3389/fonc.2020.01528 |
Related Public URLs | http://frontiersin.org/Oncology |
Files
fonc-10-01528.pdf
(10.3 Mb)
PDF
Licence
http://creativecommons.org/licenses/by/4.0/
Publisher Licence URL
http://creativecommons.org/licenses/by/4.0/
You might also like
Downloadable Citations
About USIR
Administrator e-mail: library-research@salford.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2025
Advanced Search